BridgeMD
Tests treatment safety and results for Post Inflammtory Erythema
Official title Efficacy of 0.5% Topical Timolol Eye Drops in the Treatment of Post-Inflammatory Erythema Following Acne Vulgaris
ClinicalTrials.gov ID: NCT07474883
What this study is testing
What is Timolol 0.5% Ophthalmic Solution?
Timolol 0.5% Ophthalmic Solution is an investigational medicine, given as an once-daily treatment applied to the skin, being studied as a potential treatment for post inflammtory erythema.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Post-inflammatory erythema (PIE) is a common sequela of acne vulgaris, characterized by persistent erythematous macules resulting from superficial vascular dilation. Current treatment options include energy-based devices such as intense pulsed light (IPL); however, these modalities may be costly and require specialized equipment.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 12 and older
You may be able to join if
- Participants must meet all of the following criteria:
- Age ≥ 12 years with a history of acne vulgaris.
- Clinically diagnosed with post-inflammatory erythema (PIE) secondary to acne vulgaris.
- Willing and able to provide informed consent (or assent with parental/guardian consent if under 18 years of age).
You likely can't join if
- Refusal to participate or inability to comply with study procedures (examinations, treatment, follow-up visits), or loss to follow-up.
- Presence of post-inflammatory hyperpigmentation (PIH) at the study site that may interfere with accurate assessment of erythema.
- Presence of other dermatologic conditions affecting the treatment area (e.g., atopic dermatitis, rosacea, lupus erythematosus).
- Known hypersensitivity or adverse reaction to timolol or other beta-adrenergic receptor blockers.
- Pregnant or breastfeeding women.
- History of cardiovascular or respiratory conditions contraindicating beta-blocker use (e.g., asthma, atrioventricular block, bradycardia \<50 beats...
See the full eligibility criteria
- Participants must meet all of the following criteria:
- Age ≥ 12 years with a history of acne vulgaris.
- Clinically diagnosed with post-inflammatory erythema (PIE) secondary to acne vulgaris.
- Willing and able to provide informed consent (or assent with parental/guardian consent if under 18 years of age).
- Refusal to participate or inability to comply with study procedures (examinations, treatment, follow-up visits), or loss to follow-up.
- Presence of post-inflammatory hyperpigmentation (PIH) at the study site that may interfere with accurate assessment of erythema.
- Presence of other dermatologic conditions affecting the treatment area (e.g., atopic dermatitis, rosacea, lupus erythematosus).
- Known hypersensitivity or adverse reaction to timolol or other beta-adrenergic receptor blockers.
- Pregnant or breastfeeding women.
- History of cardiovascular or respiratory conditions contraindicating beta-blocker use (e.g., asthma, atrioventricular block, bradycardia \<50 beats per minute, hypotension).
- Use of other topical medications or cosmetic products (except sunscreen) on the study area during the study period.
The study team makes the final eligibility decision.
Where it's taking place
- Ho Chi Minh City, Vietnam
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 12 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Ho Chi Minh City, Vietnam. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.